WO2022230919A1 - 細胞の製造方法 - Google Patents
細胞の製造方法 Download PDFInfo
- Publication number
- WO2022230919A1 WO2022230919A1 PCT/JP2022/019017 JP2022019017W WO2022230919A1 WO 2022230919 A1 WO2022230919 A1 WO 2022230919A1 JP 2022019017 W JP2022019017 W JP 2022019017W WO 2022230919 A1 WO2022230919 A1 WO 2022230919A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- vascular endothelial
- sinusoidal
- cell
- interleukin
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 27
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 61
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 58
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 58
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 58
- 210000000130 stem cell Anatomy 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 40
- 108090000630 Oncostatin M Proteins 0.000 claims abstract description 39
- 102000004140 Oncostatin M Human genes 0.000 claims abstract description 39
- 239000000126 substance Substances 0.000 claims abstract description 34
- 230000003511 endothelial effect Effects 0.000 claims abstract description 31
- 102000003815 Interleukin-11 Human genes 0.000 claims abstract description 25
- 108090000177 Interleukin-11 Proteins 0.000 claims abstract description 25
- 229940074383 interleukin-11 Drugs 0.000 claims abstract description 25
- 230000002792 vascular Effects 0.000 claims abstract description 18
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 134
- 230000002440 hepatic effect Effects 0.000 claims description 29
- 210000002889 endothelial cell Anatomy 0.000 claims description 26
- 210000001325 yolk sac Anatomy 0.000 claims description 18
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 16
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 16
- 230000003394 haemopoietic effect Effects 0.000 claims description 13
- 210000003462 vein Anatomy 0.000 claims description 11
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 7
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims description 6
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 6
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 6
- 108010066979 Interleukin-27 Proteins 0.000 claims description 6
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 6
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 6
- 108010041776 cardiotrophin 1 Proteins 0.000 claims description 6
- 108010002871 cardiotrophin-like cytokine Proteins 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 abstract description 4
- 239000002609 medium Substances 0.000 description 38
- 230000004069 differentiation Effects 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 19
- 239000003550 marker Substances 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 12
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 12
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 12
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 11
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 10
- 239000002771 cell marker Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 8
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102100024471 Stabilin-1 Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 6
- 101000832225 Homo sapiens Stabilin-1 Proteins 0.000 description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000001690 Factor VIII Human genes 0.000 description 5
- 108010054218 Factor VIII Proteins 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 238000002073 fluorescence micrograph Methods 0.000 description 5
- 210000001704 mesoblast Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 229960000301 factor viii Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000002220 organoid Anatomy 0.000 description 4
- 102100022464 5'-nucleotidase Human genes 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 3
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003315 endocardial cell Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108091008803 APLNR Proteins 0.000 description 2
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 2
- 102000016555 Apelin receptors Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100028226 COUP transcription factor 2 Human genes 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 2
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000860860 Homo sapiens COUP transcription factor 2 Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 2
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 2
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 2
- 102000048238 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 description 2
- 102000008790 VE-cadherin Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 210000003566 hemangioblast Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- DFFCDIMSXJYMTB-AATRIKPKSA-N 2-[(e)-2-(6-carbamimidoyl-1h-benzimidazol-2-yl)ethenyl]-3h-benzimidazole-5-carboximidamide Chemical compound C1=C(C(N)=N)C=C2NC(/C=C/C3=NC4=CC=C(C=C4N3)C(=N)N)=NC2=C1 DFFCDIMSXJYMTB-AATRIKPKSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- -1 NANOG Proteins 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710164042 Stabilin-1 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2311—Interleukin-11 (IL-11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/237—Oncostatin M [OSM]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Definitions
- the present invention relates to a method for producing sinusoidal endothelial cells from sinusoidal endothelial progenitor cells and a cell population containing sinusoidal endothelial cells.
- Sinusoidal vascular endothelial cells which constitute sinusoids, are important for maintaining the functions of parenchymal cells in the liver and bone marrow.
- cultured cells are self-organized, and three-dimensional structures of organs and complex structures of blood vessels and other vessels are created. Research and development is underway to create reproducible cell structures, i.e., organ organoids. ), it is expected that the utility value of organoids will further increase.
- Sinusoidal vascular endothelial cells from the liver, etc. are in poor condition when collected and separated from the body, and it is difficult to maintain the state and characteristics of sinusoidal vascular endothelial cells. Therefore, sinusoidal vascular endothelial cells are generally produced in a culture environment by differentiation induction from sinusoidal vascular endothelial progenitor cells, which are the progenitor cells. As methods for producing sinusoidal vascular endothelial cells, for example, the following methods are known.
- Non-Patent Document 1 after inducing differentiation from human iPS cells to hepatic sinusoidal endothelial cell precursors (LSEC progenitors), liver sinusoidal endothelial cell precursors at low oxygen concentration, TGFb1 type receptor inhibitor It is described that differentiation into CD32+ hepatic sinusoidal vascular endothelial cells (LSECs) was induced by long-term (14 days) treatment with (A83-01). The purity of hepatic sinusoidal vascular endothelial cells in the cell population obtained by the method described in Non-Patent Document 1 is about less than 40%.
- Non-Patent Document 2 after inducing differentiation from human ES cells to hemangioblasts, at hypoxic or normoxic concentrations, by treatment with AMP, TGFb inhibitor, bFGF, etc., CD32 + liver sinusoids It is described that they were induced to differentiate into vascular endothelial cells.
- the purity of hepatic sinusoidal vascular endothelial cells in the cell population obtained by the method described in Non-Patent Document 2 is 38.7% at normal oxygen concentration and 90.1% at low oxygen concentration.
- the method for producing sinusoidal vascular endothelial cells from sinusoidal vascular endothelial progenitor cells has room for improvement, such as improving the purity of sinusoidal vascular endothelial cells in the resulting cell population.
- An object of the present invention is to provide a method for producing sinusoidal vascular endothelial cells that is improved over conventional methods.
- the present inventors have found that at least one substance selected from the interleukin 6 (IL-6) family, such as interleukin 6 (IL-6), oncostatin M (OSM), interleukin 11 (IL-11) Culturing sinusoidal endothelial progenitor cells in a medium containing (cytokines, etc.) improves the purity of sinusoidal endothelial cells in the resulting cell population, especially when cultured at normal oxygen concentration It has also been found that high purities (eg, 95% or higher) can be achieved.
- IL-6 interleukin 6
- OSM oncostatin M
- IL-11 interleukin 11
- a method for producing sinusoidal endothelial cells from sinusoidal endothelial progenitor cells comprising: A method comprising culturing sinusoidal endothelial progenitor cells in a medium containing one or more substances selected from the interleukin-6 (IL-6) family.
- IL-6 interleukin-6
- one or more substances selected from the IL-6 family are at least interleukin 6 (IL-6), oncostatin M (OSM), interleukin 11 (IL-11), ciliary neurotrophic factor (CNTF) ), leukemia inhibitory factor (LIF), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine 1 (CLC), interleukin 27 (IL-27), interleukin 35 (IL-35), interleukin 35 (IL-35), The method of [1], comprising Leukin-39 (IL-39), or a combination thereof.
- the method of [1], wherein the one or more substances selected from the IL-6 family comprises at least IL-6, OSM, IL-11, or a combination thereof.
- the hepatic sinusoidal vascular endothelial progenitor cells are yolk sac vein hematopoietic vascular endothelial cells or endocardial endothelial cells, and the sinusoidal vascular endothelial cells are hepatic sinusoidal vascular endothelial cells of [1] to [4].
- the medium further contains vascular endothelial growth factor (VEGF).
- VEGF vascular endothelial growth factor
- sinusoidal vascular endothelial cells can be produced more efficiently than before, especially with high purity even at normal oxygen concentration.
- sufficiently mature sinusoidal vascular endothelial cells expressing predetermined cell markers can be produced.
- FIG. 1 shows the results of [4] “Analysis of differentiation markers of vascular endothelial cells using flow cytometry” in Example 1.
- FIG. "+OSM” indicates the case where oncostatin M was added to the medium as an IL-6 family substance, and "-OSM” indicates the case where oncostatin M was not added as a control (also in FIG. 2).
- [A] The left column shows the results of expression of CD34 (vertical axis) and CD43 (horizontal axis) of yolk sac vein hematopoietic endothelial cells (hereinafter referred to as "iVVHEC”) differentiated from iPS cells. show.
- iVVHEC yolk sac vein hematopoietic endothelial cells
- the right column shows the results of the expression of ICAM1 (vertical axis) and CD32 (horizontal axis) in (hepatic) sinusoidal vascular endothelial cells (hereinafter referred to as "iSEC") induced to differentiate from iPS cells.
- iSEC sinusoidal vascular endothelial cells
- [B] Left column shows results for iVVHEC CD34 (vertical axis) and CD43 (horizontal axis) expression.
- the right column shows the results for iSEC CD73 (vertical axis) and CD184 (horizontal axis) expression.
- FIG. 2 shows the results of [5] “Analysis of differentiation markers of cell populations by immune cell staining” in Example 1.
- the cells in "Day 10 iVVHEC” also show a certain amount of green, which indicates the expression of CD31, and white, which indicates the expression of CD32b, but the cells in "Day 20 iSEC” are strongly stained with these two colors.
- Lower row fluorescence images of CD32b, Factor VIII and DAPI.
- the cells in "Day 10 iVVHEC” also show a certain amount of red, which indicates the expression of Factor VIII, and white, which indicates the expression of CD32b, but the cells in "Day 20 iSEC” are strongly stained with those two colors.
- Fluorescence images of CD31, STAB1, LYVE1 and DAPI are [B] Fluorescence images of CD31, STAB1, LYVE1 and DAPI.
- FIG. 3 shows the results of “Analysis of differentiation markers of vascular endothelial cells using flow cytometry” in Example 2.
- (-) indicates when no IL-6 family substance was added as a control
- +IL-6, IL-11 indicates when IL-6 and IL-11 were added to the medium as IL-6 family substances
- +OSM is when oncostatin M is added to the medium as an IL-6 family substance
- +IL-6, IL-11, OSM is IL-6, IL-11 and oncostatin M as IL-6 family substances. The case where it added to the culture medium is shown, respectively.
- Liver Sinusoidal Endothelial Cell LSEC Liver Sinusoidal Endothelial Progenitor Cell: LSEPC Vitelline Venous Hemogenic Endothelial Cell VVHEC Yolk Sac Mesoderm Cell: YSMC Sinusoidal Endothelial Cell: SEC Sinusoidal Endothelial Progenitor Cell: SEPC
- pluripotent stem cell refers to a cell that can differentiate into various tissues and cells with different morphologies and functions in the body, ectoderm) refers to stem cells that have the ability to differentiate into cells of any lineage. Pluripotent stem cells that can be used in the present invention are not particularly limited. Embryonic stem cells derived from cloned embryos obtained, spermatogonial stem cells, embryonic germ cells and the like can be mentioned.
- iPS cells Induced pluripotent stem cells
- iPS cells refer to cells obtained by reprogramming mammalian somatic cells or undifferentiated stem cells by introducing specific factors (nuclear reprogramming factors).
- iPSCs induced pluripotent stem cells, and iPSCs established by Yamanaka et al. (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), and human cell-derived iPSCs established by introducing the same four factors into human fibroblasts (Takahashi K, Yamanaka S. , et al.
- Nanog-iPS cells were established by selecting Nanog expression as an indicator (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317.), iPS cells generated by c-Myc-free method (Nakagawa M, Yamanaka S., et al. Nature Biotechnology, (2008) 26, 101 - 106), iPS cells established by introducing 6 factors by virus-free method (Okita K et al. Nat. Methods 2011 May;8(5):409-12, Okita K et al. Stem Cells. 31( 3):458-66.) can also be used.
- induced pluripotent stem cells established by introducing the four factors of OCT3/4, SOX2, NANOG, and LIN28 produced by Thomson et al. (Yu J., Thomson JA. et al., Science (2007) 318: 1917-1920.), induced pluripotent stem cells produced by Daley et al. (Park IH, Daley GQ. et al., Nature (2007) 451: 141-146), induced pluripotent stem cells produced by Sakurada et al. (Japanese Unexamined Patent Application Publication No. 2008-307007) and the like can also be used.
- iPS cell lines established by NIH, RIKEN (RIKEN), Kyoto University, etc. can be used as induced pluripotent stem cells (iPS cells).
- iPS cells induced pluripotent stem cells
- human iPS cell lines RIKEN's HiPS-RIKEN-1A, HiPS-RIKEN-2A, HiPS-RIKEN-12A, and Nips-B2 strains, Kyoto University's 201B7, 253G1, and 253G4 strains, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, 625A4 strain, 648A1 strain, 1201C1 strain, 1205D1 strain, 1210B2 strain, 1231A3 strain, 1383D2 strain, 1383D6 strain, and the like.
- clinical grade cell lines provided by Kyoto University, Cellular Dynamics International, etc., and research and clinical cell lines produced using these cell lines may be used.
- mouse ESCs can use various mouse ES cell lines established by inGenious targeting laboratory, RIKEN (RIKEN), etc., and human ES cells , NIH, RIKEN, Kyoto University, and various human ES cell lines established by Cellartis are available.
- human ES cell lines include NIH CHB-1 to CHB-12, RUES1, RUES2, HUES1 to HUES28 strains, WisCell Research H1 and H9 strains, RIKEN KhES-1 and KhES- 2 strains, KhES-3 strain, KhES-4 strain, KhES-5 strain, SSES1 strain, SSES2 strain, SSES3 strain, etc. can be used.
- clinical grade cell lines and research and clinical cell lines generated using those cell lines may be used.
- the term “cell marker” refers to a gene that is specifically expressed (positive marker) or not expressed (negative marker) in a given cell type, specifically as mRNA by transcription of the gene in the genome , or a substance that is produced (positive marker) or not produced (negative marker) as a protein by translation of its mRNA.
- the cell marker is preferably a protein expressed on the cell surface (cell surface marker) that can be labeled (stained) with a fluorescent substance, and can easily detect, concentrate, isolate, etc. cells expressing the cell marker. is.
- a marker gene is "positive” means that the expression level of the mRNA or protein of the gene is detectable by a technique commonly used or known to those skilled in the art, or is lower than a predetermined threshold (background level, etc.) means high.
- Marker gene is "strongly positive” means that the expression level of mRNA or protein of the gene is “strongly positive”, which is set higher than the usual threshold value for determining whether it is “positive” is higher than a predetermined threshold for determining
- the marker gene is "negative” the expression level of mRNA or protein of the gene is undetectable or lower than a predetermined threshold (background level, etc.) by a method commonly used or known to those skilled in the art. means that
- Whether a cell marker is positive or negative can be determined with qualitative or quantitative results by methods commonly known to those skilled in the art.
- a cell marker as a protein can be detected or its expression level can be measured using an immunological assay using an antibody specific to the protein, such as ELISA, immunostaining, flow cytometry, and the like.
- Cell markers as mRNA are detected or the expression level is measured using assays using nucleic acids specific to the mRNA, such as RT-PCR (including quantitative PCR), microarrays, biochips, etc. be able to.
- the cells used in the present invention may be derived from humans or non-human animals such as mammals such as mice, rats, dogs, pigs, and monkeys.
- non-human animals such as mammals such as mice, rats, dogs, pigs, and monkeys.
- the cells are preferably derived from humans.
- “Comprise, include, contain, etc.” means the inclusion of elements following the phrase, but is not limited to this. Thus, the inclusion of the elements following the phrase, but not the exclusion of any other element, is suggested.
- “consisting of,” means including and limited to any and all elements following the phrase. Thus, the phrase “consisting of” indicates that the listed element is required or required and that other elements are substantially absent.
- “consisting essentially of, etc.” includes any element following the phrase and is limited to other elements that do not affect the activity or action specified in this disclosure for that element. means to be Thus, the phrase “consisting essentially of” indicates that the listed elements are required or required but other elements are optional and that they affect the activity or action of the listed elements. indicates that it may or may not be present, depending on whether it exerts
- the method for producing cells of the present invention is a method for producing sinusoidal vascular endothelial cells (SEC) from sinusoidal vascular endothelial progenitor cells (SEPC), wherein one selected from interleukin 6 (IL-6) family or A method comprising the step of culturing SEPCs in a medium containing more substances (hereinafter sometimes referred to as "IL-6 family substances").
- SEC sinusoidal vascular endothelial cells
- SEPC sinusoidal vascular endothelial progenitor cells
- IL-6 family substances A method comprising the step of culturing SEPCs in a medium containing more substances (hereinafter sometimes referred to as "IL-6 family substances").
- SEC Seusoidal vascular endothelial cells
- LSEC liver sinusoidal vascular endothelial cells
- LSEC vascular endothelial cells
- SEPCs Sepatic sinusoidal vascular endothelial progenitor cells
- SEPC is not limited to hepatic sinusoidal vascular endothelial progenitor cells (hepatic sinusoidal vascular endothelial progenitor cells), but also various other cells other than the liver such as bone marrow, pituitary gland, spleen, renal glomerulus, and adrenal glands.
- the progenitor cells of sinusoidal endothelial cells in the organs and tissues of can be used in the production method of the present invention.
- the production method of the present invention extracts corresponding liver and other organs from SEPCs derived from the liver and other organs and tissues. It can be used to induce differentiation of SECs derived from cells and tissues.
- the sinusoidal vascular endothelial progenitor cells are hepatic sinusoidal vascular endothelial progenitor cells (LSEPC) and the sinusoidal vascular endothelial cells (SEC) are hepatic sinusoidal vascular endothelial cells (LSEC). .
- Liver sinusoidal vascular endothelial cells are cells known to have CD32 (more specifically CD32b) and ICAM1 (CD54) as major cell markers. These cells are known to have factors, STAB1, and LYVE1 as cell markers. Specifically, when CD32 is positive and ICAM1 is strongly positive, preferably at least one (more preferably two, particularly preferably three) of factor VIII, STAB1 or LYVE1 is positive In that case, the cell can be determined to be LSEC (if the condition is not met, the cell is a cell other than LSEC).
- the vascular endothelial cell positive marker CD31 is also a positive marker for LSEC and other SECs.
- sinusoids are mainly capillary structures of the venous system, and CD73, a positive marker for venous endothelial cells, and CXCR4, a negative marker, are also positive and negative markers for LSEC and other SECs, respectively. .
- Hepatic sinusoidal vascular endothelial progenitor cells refer to cells that have the ability to differentiate into hepatic sinusoidal vascular endothelial cells (LSEC) and correspond to LSEC progenitor cells.
- LSEPCs include, for example, yolk sac venous hematopoietic vascular endothelial cells (VVHEC) and endocardial endothelial cells (EEC).
- Yolk sac vein hematopoietic vascular endothelial cells are hematopoietic vascular endothelial cells (HEC) derived from the yolk sac mesoderm, and are known to be cells responsible for hematopoiesis in the yolk sac in the early fetal period.
- VVHEC is a cell known to have CD34 as a major cell marker, as well as FN1, ACTA2 and LYVE1, and vein markers such as NR2F2, APLNR and PROX1 as cell markers.
- the cell when at least CD34 is positive and preferably at least one cell marker selected from the group consisting of FN1, ACTA2, LYVE1, NR2F2, APLNR and PROX1 is positive, the cell is VVHEC. (If the condition is not satisfied, the cell is a cell other than VVHEC).
- the vascular endothelial cell positive marker CD31 is also a positive marker for VVHEC.
- CD43 is also a negative marker for VVHEC.
- Endocardial endothelial cells are another type of endothelial cells that exist in vivo along with vascular endothelial cells.
- EEC is a cell known to have major cell markers such as CD34, CD31 and VE-cadherin, and other cell markers such as NFATC1, NRG1 and NKX2-5.
- major cell markers such as CD34, CD31 and VE-cadherin
- other cell markers such as NFATC1, NRG1 and NKX2-5.
- at least one selected from the group consisting of CD34, CD31 and VE-cadherin is positive, and preferably at least one cell marker selected from the group consisting of NFATC1, NRG1 and NKX2-5 is positive.
- the cell can be determined to be an EEC (if the condition is not met, the cell is a non-EEC cell).
- the sinusoidal endothelial progenitor cells (SEPC) used in the cell production method of the present invention can be prepared by a known method.
- pluripotent stem cells such as iPS cells and ES cells can be induced to differentiate into LSEPCs and other SEPCs (via lateral plate mesoderm cells and the like).
- Examples of such a method include a method of inducing the differentiation of pluripotent stem cells such as iPS cells into lateral plate mesoderm cells, and then further inducing the differentiation into yolk vein hematopoietic vascular endothelial cells (VVHEC) (WO2020). /203713, [2] Production of human hematopoietic vascular endothelial cells).
- SECs can be obtained by culturing SEPCs in a medium containing an IL-6 family substance.
- SEPCs are usually cultured in two-dimensional culture (flat culture).
- the culture vessel for two-dimensional culture is not particularly limited, and dishes, flasks, microplates, cell culture sheets such as the trade name "OptiCell” (Nunc) and the like can be used.
- Culture vessels are surface-treated to improve cell adhesion (hydrophilicity), collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, fibronectin, matrigel (e.g., BD Matrigel (Japan) It is preferably coated with a substrate for cell adhesion such as Becton Deckinson)), vitronectin or the like.
- a substrate for cell adhesion such as Becton Deckinson
- Substances belonging to the "IL-6 family” refer to cytokines and the like that share gp130 as a signal transducing substance (receptor). , interleukin 11 (IL-11), interleukin 27 (IL-27), interleukin 35 (IL-35), interleukin 39 (IL-39), leukemia inhibitory factor (LIF), oncostatin M (oncostatin M: OSM), cardiotrophin 1 (CT-1), ciliary neurotrophic factor (CNTF), cardiotrophin-like cytokine 1 (CLC ) are known.
- LIF leukemia inhibitory factor
- oncostatin M oncostatin M: OSM
- CT-1 cardiotrophin 1
- CNTF ciliary neurotrophic factor
- CLC cardiotrophin-like cytokine 1
- any one selected from these IL-6 families can be used singly or in combination.
- the IL-6 family substance preferably includes at least IL-6, OSM, IL-11, or any combination thereof, more preferably at least OSM. Any combination includes, for example, a combination of IL-6 and IL-11 or a combination of IL-6, IL-11 and OSM.
- the concentration of the IL-6 family substance in the medium is not particularly limited. and the composition of the medium (basal medium and other components used in combination with the IL-6 family substance).
- the concentration of the IL-6 family substance in the medium can be, for example, in the range of 5-100 ⁇ M, preferably 5-20 ⁇ M.
- basal medium for preparing the medium used in the present invention examples include DMEM/F-12 (Gibco), Stempro-34 SFM (Gibco), Essential 6 medium (Gibco), Essential 8 medium (Gibco), EGM ( Lonza), EGM-2 (Lonza), EGM-2 MV (Lonza), HCM (Gibco), BulletKit (Lonza), VascuLife EnGS Comp Kit (LCT), Human Endothelial-SFM Basal Growth Medium (Invitrogen), Human Microvascular endothelial cell growth medium (TOYOBO);
- Additives (other than IL-6 family substances) for preparing the medium used in the present invention include, for example, B27 Supplements (GIBCO), BMP4 (bone morphogenetic factor 4), GSK ⁇ inhibitor (e.g., CHIR99021), VEGF (vascular endothelial cell growth factor), FGF2 (fibroblast growth factor (bFGF (basic fibroblast growth factor))), Folskolin, SCF (stem cell factor), TGF ⁇ receptor inhibitor (e.g., SB431542), ROCK inhibitor ( Y-27632), Flt-3L (Fms-related tyrosine kinase 3 ligand), IL-3 (interleukin 3), TPO (thrombopoietin), hEGF (recombinant human epidermal growth factor), hydrocortisone, ascorbic acid , IGF1, FBS (fetal bovine serum), antibiotics (eg, gentamicin, amphotericin B), heparin, L-glut
- the medium used in the method for producing cells of the present invention preferably contains vascular endothelial growth factor (VEGF).
- VEGF vascular endothelial growth factor
- concentration of VEGF in the medium can be, for example, in the range of 5-80 ⁇ M, preferably 5-10 ⁇ M.
- Cultivation of SEPCs in the present invention can be performed at normal oxygen concentration (particularly unregulated concentration, for example, about 21%), and even in that case, a cell population with higher purity of SECs than conventional can be obtained. , at low oxygen concentrations (eg less than 10%, for example about 5%).
- the SEPC culture period in the present invention is not particularly limited, and can be, for example, a period until the number of SEPCs in the cell population is sufficiently increased to achieve the desired purity, which is usually 6 to 20 days. , preferably 6 to 14 days.
- the cell population of the present invention is a cell population containing SECs obtained by the above-described cell production method of the present invention. According to the cell production method of the present specification, a cell population with relatively high SEC purity can be obtained (without requiring separate steps such as purification, purification, and concentration).
- the purity of SEC in the cell population is not particularly limited as long as the desired degree of purity is achieved depending on the application of the cell population.
- the purity can be 80% or higher, 85% or higher, 90% or higher, or 95% or higher.
- the "purity" of a specific cell is a numerical value represented by the ratio of the number of cells to the total number of cells in the cell population. It can be measured by a simple method. Also in the present invention, for example, samples are collected from the cell population obtained by the method for producing cells of the present invention, and fluorescent immunostaining is performed for SEC cell markers (e.g., markers described separately herein). After that, the purity of SECs in that cell population can be determined by measurement using flow cytometry.
- the use of the cell population of the present invention is not particularly limited, and can be used for various purposes using SEC.
- the SECs contained in) the cell populations of the present invention can be utilized to generate organoids or three-dimensional organs of sinusoidal organs or tissues such as liver, bone marrow, and the like.
- Day represents the number of days from the initiation of differentiation induction of human iPS cell colonies.
- Day 0 is the start of the culture in step [1] below.
- Example 1 Preparation of hepatic sinusoidal vascular endothelial cells by addition of oncostatin M [experimental method] [1] Preparation of human yolk sac mesoderm cells Human iPS cells (625A4; iPS Research Institute, Kyoto University) were placed in AK02N (Ajinomoto) (10 cm dish; 8 ml, 24-well plate; 0.5 ml) in 5% CO 2 , Culture was continued at 37° C. until iPS cell colonies with a diameter of 500-700 ⁇ m were formed (about 6-7 days).
- the resulting colonies were added to Essential 8 medium (Gibco) (10 cm dish; 8 ml, 24-well plate; 0.5 ml) with BMP4 (80 ng/ml), VEGF (80 ng/ml) and CHIR99021 (2 ⁇ M).
- Essential 8 medium Gibco
- BMP4 80 ng/ml
- VEGF 80 ng/ml
- CHIR99021 2 ⁇ M
- Human yolk sac mesoderm cells were produced by culturing in a medium at 5% CO 2 at 37° C. for 2 days (Day 0-2).
- Stempro-34 SFM (Gibco) (10 cm dish; 8 ml) was added with VEGF (80 ng/ml), SCF (50 ng/ml), Flt-3L (50 ng/ml), IL-3 (50 ng/ml), IL- 6 (50 ng/ml) and TPO (5 ng/ml) were added to the medium, cultured at 5% CO 2 at 37° C. for 2 days (Day 5-6), and VEGF was removed from the medium having the above composition.
- CD34-positive and CD32-positive yolk sac vein hematopoietic endothelial cells (iVVHEC) were induced by replacing the medium and culturing at 37° C. in 5% CO 2 for 2 days (Day 7-8).
- the cells were suspended in a PBS(-) buffer containing 1 mM EDTA and 4% FBS and counted. Dispense 1 ⁇ 10 8 or less cells, centrifuge under the same conditions, suspend in PBS(-) buffer containing 300 ⁇ l of 1 mM EDTA and 4% FBS, and add 1 ⁇ l per 1 ⁇ 10 6 cells.
- a CD34 MicroBead Kit (Miltenyi) was added, mixed, and left on ice for 30 minutes.
- EGM (Lonza) medium at a volume ratio of 1:1, VEGF (5 ng/mL), Y-27632 (10 ⁇ M) (Fujifilm Wako Pure Chemical Industries, Ltd.) were added to the hepatic sinusoidal endothelial cell induction medium.
- 1 ⁇ 10 5 cells and 2 ⁇ 10 5 cells were coated on a 24-well plate or a 12-well plate, respectively, coated with Matrigel (BD Pharmingen) diluted 50-fold with PBS(-) at 37° C. for 30 minutes.
- the cells were seeded and cultured at 37° C. in 5% CO 2 for 6 days or longer (Days 9-14 and thereafter) to obtain cell populations containing hepatic sinusoidal vascular endothelial cells.
- the medium was exchanged with a hepatic sinusoidal vascular endothelial cell-inducing medium excluding Y-27632 (10 ⁇ M) the next day after seeding, and then every two days.
- yolk sac vein hematopoietic vascular endothelial cells were cultured in the same manner as above except that OSM (final concentration 10 ng/ml) was not added to obtain a cell population containing hepatic sinusoidal vascular endothelial cells.
- Fig. 1 [A] The results are shown in Fig. 1 [A]. It can be seen that the production method of the present invention using oncostatin M yielded a cell population containing CD32 + ICAM1 (CD54) ++ LSEC (iSEC) with extremely high purity (95% or more) from CD34 + VVHEC (iVVHEC).
- the primary antibody solution was 1/50 PE-CD184 (BioLegend, Cat: 306506), BV421-CD34 (BD Biosciences, Cat: 562577), APC-CD73 (Miltenyi Biotec, Cat: 130-095-183), BV786-CD43 (BD Biosciences, Cat: 744662) in BD Horizon Brilliant TM Stain Buffer was used in the same manner as described above to obtain an antibody-stained cell suspension and analyze differentiation markers by flow cytometry. did. The results are shown in FIG. 1[B].
- the cell population obtained by the production method of the present invention using oncostatin M contains cells having CD73+CXCR4-, indicating that oncostatin induces this surface marker profile of venous vascular endothelial cells.
- LSEC contained in the cell population obtained by the production method of the present invention not only expresses (positive) CD31 and CD32 on the cell surface, but also secretes a large amount of factor VIII protein. I know there is.
- the primary antibody solution was 1/100 Anti- Stabilin-1 (NOVUS Bio, H00023166-M05), 1/100 Anti-CD31 (Abcam, ab28364), 1/100 Anti-LYVE1 (R&D, AF2089) antibodies Set the secondary antibody solution to the secondary antibody corresponding to each primary antibody (1/1000, Alexa Flor 555, 1/1000, Alexa Flor 594, 1/1000, Alexa Flor 647) and 1/1000 DAPI-HCB (Hycult Biotech, HM2167) was added to the solution, but immunocytostaining was performed in the same manner as above. As a control, immune cell staining was also performed on the cells in which oncostatin M was not added in steps [1] to [3].
- LSECs contained in the cell population obtained by the production method of the present invention express STAB1 and LYVE1 proteins as sinusoidal endothelial markers in addition to the CD32 and factor VIII proteins described above. .
- Example 2 Preparation of hepatic sinusoidal vascular endothelial cells by adding IL-6 and IL-11 After performing the steps [1] and [2] in the same manner as in Example 1, in step [3], A cell population containing hepatic sinusoidal endothelial cells was obtained by using any one of the following 1) to 3) as the hepatic sinusoidal endothelial cell induction medium. 2) is obtained by repeating substantially the same steps as in the first embodiment. 1) Mix EGM (Lonza) medium with 5% FBS Gold (Biosera), IL-6 (10 ng/ml) and IL-11 (5 ng/ml) in HCM (Lonza) at a volume ratio of 1:1.
- VEGF 5 ng/mL
- Y-27632 10 ⁇ M
- HCM hepatic sinusoidal endothelial cell induction medium 2
- VEGF (5 ng/mL) and Y-27632 (10 ⁇ M) were added to a 1:1 volume ratio of EGM (Lonza) medium and EGM (Lonza) medium to induce liver sinusoidal endothelial cells 3) HCM (Lonza) 5% FBS Gold (Biosera), IL-6 (10ng/ml), IL-11 (5ng/ml) and OSM (20ng/ml) mixed with EGM (Lonza) medium at a volume ratio of 1:1 Liver sinusoidal endothelial cell induction medium with VEGF (5 ng/mL) and Y-27632 (10 ⁇ M) added to
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]
類洞血管内皮前駆細胞から類洞血管内皮細胞を製造する方法であって、
インターロイキン6(IL-6)ファミリーから選択される一種またはそれ以上の物質を含む培地で類洞血管内皮前駆細胞を培養する工程を含む方法。
[2]
IL-6ファミリーから選択される一種またはそれ以上の物質が、少なくともインターロイキン6(IL-6)、オンコスタチンM(OSM)、インターロイキン11(IL-11)、毛様体神経栄養因子(CNTF)、白血病阻止因子(LIF)、カルジオトロフィン1(CT-1)、カルジオトロフィン様サイトカイン1(CLC)、インターロイキン27(IL-27)、インターロイキン35(IL-35)、インターロイキン39(IL-39)、または、それらの組み合わせを含む、[1]に記載の方法。
[3]
IL-6ファミリーから選択される一種またはそれ以上の物質が、少なくともIL-6、OSM、IL-11、またはそれらの組み合わせを含む、[1]に記載の方法。
[3a]
IL-6ファミリーから選択される一種またはそれ以上の物質が、IL-6、OSM、IL-11、またはそれらの組み合わせである、[1]に記載の方法。
[4]
IL-6ファミリーから選択される一種またはそれ以上の物質が、少なくともOSMを含む、[1]に記載の方法。
[4a]
IL-6ファミリーから選択される一種またはそれ以上の物質が、OSMである、[1]に記載の方法。
[5]
類洞血管内皮前駆細胞が、肝類洞血管内皮前駆細胞であり、類洞血管内皮細胞が、肝類洞血管内皮細胞である、[1]~[4]のいずれか一項に記載の方法。
[5a]
肝類洞血管内皮前駆細胞が、卵黄嚢静脈造血性血管内皮細胞または心内膜内皮細胞であり、類洞血管内皮細胞が、肝類洞血管内皮細胞である、[1]~[4]のいずれか一項に記載の方法。
[6]
肝類洞血管内皮前駆細胞が、卵黄嚢静脈造血性血管内皮細胞である、[5]に記載の方法。
[7]
前記培地が、血管内皮細胞成長因子(VEGF)をさらに含む、[1]~[6]のいずれか一項に記載の方法。
[8]
前記類洞血管内皮前駆細胞が多能性幹細胞から誘導されたものである[1]~[7]のいずれか一項に記載の方法。
[9]
[1]~[8]のいずれか一項に記載の方法により得られた類洞血管内皮細胞を含む細胞集団。
・略語
本明細書では、以下の略語を用いることがある。
肝類洞血管内皮細胞(Liver Sinusoidal Endothelial Cell):LSEC
肝類洞血管内皮前駆細胞(Liver Sinusoidal Endothelial Progenitor Cell):LSEPC
卵黄嚢静脈造血性血管内皮細胞(Vitelline Venous Hemogenic Endothelial Cell)VVHEC
卵黄嚢中胚葉(Yolk Sac Mesoderm Cell):YSMC
類洞血管内皮細胞(Sinusoidal Endothelial Cell):SEC
類洞血管内皮前駆細胞(Sinusoidal Endothelial Progenitor Cell):SEPC
本明細書において「多能性幹細胞(pluripotent stem cell)」とは、生体の種々の異なった形態や機能を持つ組織や細胞に分化でき、三胚葉(内胚葉、中胚葉、外胚葉)のどの系統の細胞にも分化し得る能力を有する幹細胞を指す。本発明において使用可能な多能性幹細胞は、特に限定されないが、例えば、人工多能性幹細胞(iPS細胞と称することもある)、胚性幹細胞(ES細胞と称することもある)、核移植により得られるクローン胚由来の胚性幹細胞、精子幹細胞、胚性生殖細胞などが挙げられる。
本明細書において「細胞マーカー」は、所定の細胞型において特異的に発現する(陽性マーカー)または発現しない(陰性マーカー)遺伝子、具体的にはゲノム中の当該遺伝子の転写によるmRNAとして、またはそのmRNAの翻訳によるタンパク質として、生成する(陽性マーカー)または生成しない(陰性マーカー)物質を指す。細胞マーカーは、好ましくは蛍光物質により標識(染色)可能であり、当該細胞マーカーを発現している細胞の検出、濃縮、単離等を容易に行える、細胞表面に発現するタンパク質(細胞表面マーカー)である。
本発明の細胞の製造方法は、類洞血管内皮前駆細胞(SEPC)から類洞血管内皮細胞(SEC)を製造する方法であって、インターロイキン6(IL-6)ファミリーから選択される一種またはそれ以上の物質(以下「IL-6ファミリー物質」と表記することがある。)を含む培地でSEPCを培養する工程を含む方法である。
本発明の細胞集団は、上述した本発明の細胞の製造方法により得られたSECを含む細胞集団である。本明細書の細胞の製造方法により、SECの純度が比較的高い細胞集団を(別途の純化、精製、濃縮等の工程を要することなく)得ることができる。
[実験方法]
[1]ヒト卵黄嚢中胚葉細胞の作製
ヒトiPS細胞(625A4;京都大学iPS研究所)を、AK02N(味の素)(10cm dish; 8ml、24-well plate; 0.5ml)中、5%CO2、37℃で直径500-700μmのiPS細胞コロニーが形成されるまで(約6~7日間)培養を行なった。得られたコロニーを、Essential 8培地(Gibco) (10cm dish; 8ml、24-well plate; 0.5ml)にBMP4(80 ng/ml)、VEGF(80 ng/ml)およびCHIR99021(2μM)を添加した培地中、5%CO2、37℃で2日間培養し、ヒト卵黄嚢中胚葉細胞を作製した(Day 0-2)。
[1]ヒト卵黄嚢中胚葉細胞の作製に引き続き、Essential 6培地(Gibco)(10cm dish; 8ml)にVEGF(80ng/ml)、FGF2(25ng/ml)、SCF(50ng/ml)およびSB431542(2μM)を添加した培地に交換し、5%CO2、37℃でさらに2日間培養することで血球‐血管内皮共通前駆細胞を誘導した(Day 3-4)。その後、Stempro-34 SFM(Gibco)(10cm dish; 8ml)にVEGF(80ng/ml)、SCF(50ng/ml)、Flt-3L(50ng/ml)、IL-3(50ng/ml)、IL-6(50ng/ml)およびTPO(5ng/ml)を添加した培地に交換し、5%CO2、37℃で2日間培養した後(Day 5-6)、上記組成の培地からVEGFを除いた培地に交換して、5%CO2、37℃で2日間培養することで(Day 7-8)、CD34陽性、CD32陽性の卵黄嚢静脈造血性血管内皮細胞(iVVHEC)を誘導した。
[2]の工程で得られたCD34陽性、CD32陽性のヒト卵黄嚢静脈造血性血管内皮細胞を含む細胞集団に対して、TrypLe Express(Gibco)を37℃、15分反応させ、その後P1000 マイクロピペットによるピペッティングにより、細胞を乖離しながら15mLチューブへ回収し、Stempro-34 SFM(Gibco)培地を7mL添加した後、1000 rpm、室温、5分間遠心分離した。上清を除去後、1mM EDTA、4% FBS を含むPBS(-)バッファで懸濁し、セルカウントを実施した。1×108個以下の細胞を分注し、同様の条件で遠心分離した後、300μlの1mM EDTA、4% FBS を含むPBS(-)バッファに懸濁し、1×106個細胞あたり1μlのCD34 MicroBead Kit (Miltenyi)を加え、混和し、氷上で30分間静置した。次いで1mM EDTA、4% FBS を含むPBS(-)バッファで2回洗浄後、同様のバッファ500 μlにて懸濁し、QuadroMACS SeparatorおよびLS Column(Miltenyi)を用いて、CD34陽性の卵黄嚢静脈造血性血管内皮細胞を純化取得した。純化した細胞懸濁液を1000 rpm、室温、5分間遠心分離し、上清を除去後、HCM(Lonza)に5% FBS Gold(Biosera),OSM(20ng/ml)(R&D)を加えた培地とEGM(Lonza)培地を1:1体積割合で混合したものにVEGF(5ng/mL)、Y-27632(10μM)(富士フィルム和光純薬)を加えた肝類洞血管内皮細胞誘導培地に懸濁後、PBS(-)にて50倍希釈したマトリゲル(BD Pharmingen)で37℃、30分コーティングした24 well plateまたは12 well plateにそれぞれ、1×105個、2×105個の細胞を播種し、5%CO2、37℃で6日間以上(Day 9-14およびそれ以降)、培養し、肝類洞血管内皮細胞を含む細胞集団を得た。培地交換は播種後翌日にY-27632(10μM)を除いた肝類洞血管内皮細胞誘導培地に交換後、2日おきに実施した。
[1]―[3]の工程で12 well plateを用いて分化誘導を実施後、培地を除去してPBS(-)(GIBCO)で2回洗浄後、TrypLE Express(Gibco)を1mL/wellの容量で添加して15分間37℃で放置した。その後P1000 マイクロピペットによるピペッティングにより、細胞を乖離しながら15mLチューブへ回収し、Stempro-34 SFM(Gibco)培地を5mL添加した後、1000 rpm、室温、5分間遠心分離した。上清を除去後、1mM EDTA、4% FBS を含むPBS(-)バッファを用いて1度洗浄後、1次抗体溶液(1/50 PE-CD32(BioLegend, Cat: 303205), BV421-CD34(BD Biosciences, Cat: 562577),APC-CD54(BD Biosciences, Cat: 559771),BV786-CD43(BD Biosciences, Cat: 744662)in BD Horizon BrilliantTM Stain Buffer)50μlにて細胞を懸濁し、氷上で30分間静置した。次いで1mM EDTA、4% FBS を含むPBS(-)バッファで2回洗浄後、1/1000 DAPI、1mM EDTA、4% FBS を含むPBS(-)バッファにて細胞を懸濁し、40μmセルストレーナーキャップ付きチューブに移した。得られた抗体染色細胞懸濁液を用いて、BD LSRFortessa フローサイトメトリーによって分化マーカーの解析を実施した。フローサイトメトリーから得られたデータの解析は、FlowJo 10.7.1 (BD)を用いて実施した。
[1]―[3]の工程で24 well plateを用いて分化誘導を実施後、培地を除去してPBS(-)(GIBCO)で1回洗浄後、細胞に4%パラホルムアルデヒドを500μl/24 wellの容量で添加して15分間室温で放置した。その後PBS(-)で3回洗浄し、4℃で一晩保存した。その後細胞にPROTEIN BLOCK SERUM-FREE blocking溶液[DAKO, X909]を500μl/24wellの容量で添加して60分間室温で放置してブロッキングをおこなった。その後、0.1% Donkey Serumを含むPBS(-)に、ターゲットとなる抗原に対する1次抗体をウェルごとに異なる組み合わせ(1/100 Anti-Factor VIII (Abcam, ab41188), 1/500 Anti-CD32b (Abcam, ab151497)の抗体セットまたは、 1/50 Anti-CD31 (Abcam, ab24590), 1/500 Anti-CD32b (Abcam, ab151497)の抗体セット)にて加えた1次抗体溶液を、各ウェルに対して500μl/24wellの容量で添加し、室温60分または4℃で一晩静置した。次いでPBS(-)で3回洗浄後、1% blocking溶液 in PBS(-)に各1次抗体に対応する2次抗体(1/1000, Alexa Flour 555, 1/1000, Alexa Flour 647)および1/1000 DAPI-HCB Hycult Biotech, HM2167)加えた、2次抗体溶液を500μl/24wellの容量で添加し、室温で60分インキュベートした。その後PBS(-)で3回洗浄後、PBS(-)500μl/24wellの容量で添加、保持し、BZ-X700蛍光顕微鏡 (Keyence)を用いて蛍光画像の取得を実施した。
実施例1と同様に[1]および[2]の工程を行った後、[3]の工程において、「肝類洞血管内皮細胞誘導培地」として、下記1)~3)のいずれかを用いるようにして、肝類洞血管内皮細胞を含む細胞集団を得た。なお、2)は、実施例1と実質的に同じ工程を繰り返したものである。
1)HCM(Lonza)に5% FBS Gold(Biosera),IL-6(10ng/ml)およびIL-11(5ng/ml)を加えた培地とEGM(Lonza)培地を1:1体積割合で混合したものにVEGF(5ng/mL)、Y-27632(10μM)を加えた肝類洞血管内皮細胞誘導培地
2)HCM(Lonza)に5% FBS Gold(Biosera),OSM(20ng/ml)を加えた培地とEGM(Lonza)培地を1:1体積割合で混合したものにVEGF(5ng/mL)、Y-27632(10μM)を加えた肝類洞血管内皮細胞誘導培地
3)HCM(Lonza)に5% FBS Gold(Biosera),IL-6(10ng/ml),IL-11(5ng/ml)およびOSM(20ng/ml)を加えた培地とEGM(Lonza)培地を1:1体積割合で混合したものにVEGF(5ng/mL)、Y-27632(10μM)を加えた肝類洞血管内皮細胞誘導培地
Claims (9)
- 類洞血管内皮前駆細胞から類洞血管内皮細胞を製造する方法であって、
インターロイキン6(IL-6)ファミリーから選択される一種またはそれ以上の物質を含む培地で類洞血管内皮前駆細胞を培養する工程を含む方法。 - IL-6ファミリーから選択される一種またはそれ以上の物質が、少なくともインターロイキン6(IL-6)、オンコスタチンM(OSM)、インターロイキン11(IL-11)、毛様体神経栄養因子(CNTF)、白血病阻止因子(LIF)、カルジオトロフィン1(CT-1)、カルジオトロフィン様サイトカイン1(CLC)、インターロイキン27(IL-27)、インターロイキン35(IL-35)、インターロイキン39(IL-39)、または、それらの組み合わせを含む、請求項1に記載の方法。
- IL-6ファミリーから選択される一種またはそれ以上の物質が、少なくともIL-6、OSM、IL-11、またはそれらの組み合わせを含む、請求項1に記載の方法。
- IL-6ファミリーから選択される一種またはそれ以上の物質が、少なくともOSMを含む、請求項1に記載の方法。
- 類洞血管内皮前駆細胞が、肝類洞血管内皮前駆細胞であり、類洞血管内皮細胞が、肝類洞血管内皮細胞である、請求項1に記載の方法。
- 肝類洞血管内皮前駆細胞が、卵黄嚢静脈造血性血管内皮細胞である、請求項5に記載の方法。
- 前記培地が、血管内皮細胞成長因子(VEGF)をさらに含む、請求項1に記載の方法。
- 前記類洞血管内皮前駆細胞が多能性幹細胞から誘導されたものである、請求項1に記載の方法。
- 請求項1に記載の方法により得られた類洞血管内皮細胞を含む細胞集団。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22795832.9A EP4332215A1 (en) | 2021-04-28 | 2022-04-27 | Method for producing cells |
JP2023517585A JPWO2022230919A1 (ja) | 2021-04-28 | 2022-04-27 | |
US18/557,836 US20240228972A1 (en) | 2021-04-28 | 2022-04-27 | Method for producing cells |
CN202280031352.6A CN117242171A (zh) | 2021-04-28 | 2022-04-27 | 用于产生细胞的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-075780 | 2021-04-28 | ||
JP2021075780 | 2021-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022230919A1 true WO2022230919A1 (ja) | 2022-11-03 |
Family
ID=83848502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/019017 WO2022230919A1 (ja) | 2021-04-28 | 2022-04-27 | 細胞の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240228972A1 (ja) |
EP (1) | EP4332215A1 (ja) |
JP (1) | JPWO2022230919A1 (ja) |
CN (1) | CN117242171A (ja) |
WO (1) | WO2022230919A1 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003111588A (ja) * | 2000-01-11 | 2003-04-15 | Geron Corp | ヒト多能性幹細胞の増殖および分化のための技術 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
US20080236610A1 (en) | 2004-04-10 | 2008-10-02 | Holger Bartels | Hair Rollers |
WO2008118220A2 (en) | 2006-11-28 | 2008-10-02 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
WO2008124133A1 (en) | 2007-04-07 | 2008-10-16 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
WO2008151058A2 (en) | 2007-05-30 | 2008-12-11 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US20090047263A1 (en) | 2005-12-13 | 2009-02-19 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
WO2016148216A1 (ja) * | 2015-03-18 | 2016-09-22 | 国立大学法人 東京大学 | 肝細胞及び肝非実質細胞、並びにそれらの調製方法 |
JP2019533452A (ja) * | 2016-11-04 | 2019-11-21 | チルドレンズ ホスピタル メディカル センター | 肝臓オルガノイド組成物ならびにその作製および使用方法 |
WO2020204149A1 (ja) * | 2019-03-29 | 2020-10-08 | 公立大学法人横浜市立大学 | スクリーニング方法および毒性評価法 |
WO2020203713A1 (ja) | 2019-03-29 | 2020-10-08 | 公立大学法人横浜市立大学 | マトリックス組成物 |
-
2022
- 2022-04-27 US US18/557,836 patent/US20240228972A1/en active Pending
- 2022-04-27 WO PCT/JP2022/019017 patent/WO2022230919A1/ja active Application Filing
- 2022-04-27 EP EP22795832.9A patent/EP4332215A1/en active Pending
- 2022-04-27 JP JP2023517585A patent/JPWO2022230919A1/ja active Pending
- 2022-04-27 CN CN202280031352.6A patent/CN117242171A/zh active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003111588A (ja) * | 2000-01-11 | 2003-04-15 | Geron Corp | ヒト多能性幹細胞の増殖および分化のための技術 |
US20080236610A1 (en) | 2004-04-10 | 2008-10-02 | Holger Bartels | Hair Rollers |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
JP2008283972A (ja) | 2005-12-13 | 2008-11-27 | Kyoto Univ | 誘導多能性幹細胞の製造方法 |
US20090047263A1 (en) | 2005-12-13 | 2009-02-19 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
WO2008118220A2 (en) | 2006-11-28 | 2008-10-02 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
WO2008124133A1 (en) | 2007-04-07 | 2008-10-16 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
WO2008151058A2 (en) | 2007-05-30 | 2008-12-11 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
WO2009006997A1 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc. | Human pluripotent stem cells and their medical use |
WO2009006930A1 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc. | Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue |
WO2009007852A2 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc | Multipotent/pluripotent cells and methods |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
WO2016148216A1 (ja) * | 2015-03-18 | 2016-09-22 | 国立大学法人 東京大学 | 肝細胞及び肝非実質細胞、並びにそれらの調製方法 |
JP2019533452A (ja) * | 2016-11-04 | 2019-11-21 | チルドレンズ ホスピタル メディカル センター | 肝臓オルガノイド組成物ならびにその作製および使用方法 |
WO2020204149A1 (ja) * | 2019-03-29 | 2020-10-08 | 公立大学法人横浜市立大学 | スクリーニング方法および毒性評価法 |
WO2020203713A1 (ja) | 2019-03-29 | 2020-10-08 | 公立大学法人横浜市立大学 | マトリックス組成物 |
Non-Patent Citations (14)
Title |
---|
GAGE ET AL., CELL STEM CELL, vol. 27, 2020, pages 254 - 269 |
HUANGFU D.MELTON, DA. ET AL., NATURE BIOTECHNOLOGY, vol. 26, no. 7, 2008, pages 795 - 797 |
KIM JB.SCHOLER HR. ET AL., NATURE, vol. 454, 2008, pages 646 - 650 |
KOUI ET AL., STEM CELL REPORTS, vol. 9, 2017, pages 490 - 498 |
MATSUBARA ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 515, no. 1, 2019 |
OHTA, R. ET AL., J. VIS. EXP., vol. 148, 2019, pages 59823 |
OKITA K ET AL., NAT. METHODS, vol. 8, no. 5, May 2011 (2011-05-01), pages 409 - 12 |
OKITA K ET AL., STEM CELLS., vol. 31, no. 3, pages 458 - 66 |
OKITA, K.ICHISAKA, T.YAMANAKA, S., NATURE, vol. 451, 2007, pages 141 - 146 |
SHI Y.DING S. ET AL., CELL STEM CELL, vol. 3, 2008, pages 568 - 574 |
TAKAHASHI KYAMANAKA S. ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
TAKAHASHI KYAMANAKA S., CELL, vol. 126, 2006, pages 663 - 676 |
YU J.THOMSON JA. ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
YUTA KOUI, ET AL.: "An In Vitro Human Liver Model by iPSC-Derived Parenchymal and Non-parenchymal Cells", STEM CELL REPORTS, CELL PRESS, UNITED STATES, vol. 9, no. 2, 1 August 2017 (2017-08-01), United States , pages 490 - 498, XP055694369, ISSN: 2213-6711, DOI: 10.1016/j.stemcr.2017.06.010 * |
Also Published As
Publication number | Publication date |
---|---|
EP4332215A1 (en) | 2024-03-06 |
CN117242171A (zh) | 2023-12-15 |
JPWO2022230919A1 (ja) | 2022-11-03 |
US20240228972A1 (en) | 2024-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2970912T3 (en) | Methods and Materials for Hematoendothelial Differentiation of Human Pluripotent Stem Cells under Defined Conditions | |
KR102416647B1 (ko) | 췌장 전구 세포의 증식 방법 | |
US8507275B2 (en) | Method of inducing differentiation of embryonic stem cells into hemangioblast | |
JP7176764B2 (ja) | ナイーブ型多能性幹細胞からの原始内胚葉誘導方法 | |
US11959100B2 (en) | Method for culture of cells | |
KR20130112862A (ko) | 투석된 혈청이 있는 심근세포 배지 | |
Wang et al. | Apela promotes cardiomyocyte differentiation from transgenic human embryonic stem cell lines | |
WO2020250913A1 (ja) | 腎間質細胞の製造方法 | |
WO2022230919A1 (ja) | 細胞の製造方法 | |
KR102049211B1 (ko) | 내피세포의 제조 방법 | |
Jankowska-Steifer et al. | Cells with hematopoietic potential reside within mouse proepicardium | |
US20220252575A1 (en) | Screening method and toxicity evaluation method | |
JP7501875B2 (ja) | 血液凝固および/または補体異常疾患の治療用組成物 | |
WO2022191171A1 (ja) | 細胞クラスターの製造方法 | |
EP3875578A1 (en) | Method for producing pluripotent stem cell having released differentiation resistance to mesendoderm | |
WO2019189554A1 (ja) | 心筋細胞成熟促進剤 | |
JP7446242B2 (ja) | 胚型赤芽球を含む細胞集団及びその製造方法、細胞培養組成物並びに化合物試験法 | |
WO2023156774A1 (en) | Generating bone marrow organoids | |
JP2024531682A (ja) | コミットされた心臓始原細胞の製造方法 | |
EA044339B1 (ru) | Способ культивирования клеток |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22795832 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023517585 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280031352.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18557836 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022795832 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022795832 Country of ref document: EP Effective date: 20231128 |